Key result
Selective thrombophilia testing guides targeted VTE prevention and therapy based on patient risk.
Why the study?
It is crucial to identify which patients with deep venous thrombosis benefit from thrombophilia testing to guide prevention and therapy strategies.
A combined clinical and laboratory approach is recommended to tailor thrombophilia testing programs to individual patients to benefit prevention and therapy of venous thromboembolism.
Answers are grounded in this paper and cite their sources.
May support selective thrombophilia testing in DVT; hypothesis-generating and should not yet change practice.
In the past 3 decades, numerous biological abnormalities linked with deep venous thrombosis have been described. Among the different possibilities, it is crucial to order tests that can modify the therapeutic attitude towards the patient and/or his family. A combined clinical and laboratory approach taking into account the history of the patient and his family, the prevalence of the defects, and also the accuracy of the tests should allow tailoring a laboratory testing program to each patient. It is essential to keep in mind that the more difficult task is not to perform the tests but to consider who will benefit from testing both for prevention and therapy of venous thromboembolism. This article provides answers to some of these issues. These answers should, however, be considered as tentative and provisional because new findings and study results will certainly modify them in the near future.
No takes yet. Share an insight, caveat, or question.
Moerloose et al. (2001) conducted a review in Deep venous thrombosis and thrombophilia. Thrombophilia testing was evaluated. Tailoring thrombophilia testing based on clinical history, defect prevalence, and test accuracy is crucial to identify patients who will benefit in the prevention and therapy of venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: